Welcome to our dedicated page for Ascentage Pharma Group International SEC filings (Ticker: AAPG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ascentage Pharma Group International furnishes SEC filings as a foreign private issuer reporting under Form 6-K and indicating annual reporting on Form 20-F. The filings document press releases and Hong Kong Stock Exchange announcements for annual results, oncology pipeline updates, clinical and preclinical presentation materials, and changes in corporate administration.
The company’s filing record also includes Hong Kong annual report and environmental, social and governance materials, annual general meeting notices, proxy forms, director re-election matters, general mandates to issue or repurchase shares, and supplemental equity-incentive grant proposals under its RSU and post-IPO share option schemes.
Ascentage Pharma Group International furnished a Form 6-K to share a press release about upcoming scientific and investor visibility events. The company will feature 17 clinical advances at the 31st European Hematology Association Congress in Stockholm from June 11 to 14, 2026, including 8 poster presentations.
The abstracts highlight ongoing studies of Olverembatinib, China’s first approved third-generation BCR-ABL1 inhibitor, and Lisaftoclax, the first China-developed Bcl-2 selective inhibitor. The release also describes multiple global registrational Phase III trials across leukemias, lymphomas, AML, GIST and higher-risk MDS, underscoring Ascentage Pharma’s broad late-stage pipeline.
Ascentage Pharma Group International furnished a Form 6-K to share a press release announcing that its management is scheduled to participate in three upcoming investor conferences. Webcasts of a fireside chat and presentation will be available through the Events page of the company’s Investor Relations website.
The filing also reiterates that Ascentage Pharma is a global, commercial stage biopharmaceutical company focused on novel cancer therapies, with two approved products in China and multiple ongoing global registrational Phase III trials across leukemia, lymphoma, acute myeloid leukemia, higher-risk myelodysplastic syndromes, and other tumor types.
Ascentage Pharma Group International furnished a Form 6-K to share a press release announcing that its management is scheduled to participate in three upcoming investor conferences. Webcasts of a fireside chat and presentation will be available through the Events page of the company’s Investor Relations website.
The filing also reiterates that Ascentage Pharma is a global, commercial stage biopharmaceutical company focused on novel cancer therapies, with two approved products in China and multiple ongoing global registrational Phase III trials across leukemia, lymphoma, acute myeloid leukemia, higher-risk myelodysplastic syndromes, and other tumor types.
Ascentage Pharma Group International filed a Form 6-K to furnish its Hong Kong annual report, ESG report, AGM notice and related proxy materials to U.S. investors. The AGM will be held on May 20, 2026 at 10:00 a.m. in Suzhou, China.
Shareholders are asked to re-elect three directors, re-appoint Ernst & Young as auditor for 2026 with estimated fees of RMB5.1 million, and renew general mandates to issue shares and to repurchase up to 10% of issued shares. As at the Latest Practicable Date, issued share capital comprised 373,334,750 shares, implying a potential buyback of 37,333,475 shares under the mandate.
The company also proposes a third amended and restated memorandum and articles of association to permit hybrid and fully electronic general meetings and electronic voting, and to align with updated Hong Kong and Cayman rules on treasury shares and meeting mechanics.
Ascentage Pharma Group International files its annual Form 20-F, detailing a development-stage oncology business with significant ongoing losses and heavy R&D investment. The company reported a net loss of RMB1,243.0 million (US$177.7 million) for 2025 and accumulated losses of RMB7,013.3 million (US$1,002.9 million) as of December 31, 2025.
Revenue came mainly from product sales and collaborations, totaling RMB574.1 million (US$82.1 million) in 2025. Ascentage held RMB2,470.1 million (US$353.2 million) in cash and bank balances and had secured bank loans of RMB600.2 million (US$85.8 million), partially collateralized by buildings and right-of-use assets. Management believes existing cash and a loan facility can fund operations for at least 12 months, but not all programs through approval.
The report highlights dependence on two commercialized products in China—Olverembatinib and Lisaftoclax—ongoing global clinical trials, and substantial regulatory, financing and clinical risks. Shares are listed via American depositary shares on Nasdaq, each ADS representing four ordinary shares, with 373,322,192 ordinary shares outstanding as of April 1, 2026. Financial statements are prepared under IFRS and presented in RMB.
Ascentage Pharma Group International filed a report highlighting upcoming scientific presentations at the 2026 ASCO Annual Meeting. Six abstracts from clinical studies of three key cancer drug candidates have been accepted, including three rapid oral presentations and three poster presentations.
The work centers on Olverembatinib, Lisaftoclax and Alrizomadlin across leukemias, soft-tissue sarcomas and SDH-deficient tumors. The company also reiterates that Olverembatinib and Lisaftoclax are already approved in China for specific hematologic cancers and describes multiple ongoing global Phase III registrational trials for these agents.
Misra Veet reported acquisition or exercise transactions in this Form 4 filing.
Ascentage Pharma Group International reported a compensation-related equity grant to its Chief Financial Officer, Veet Misra. The filing shows an award of 18,584 restricted stock units (RSUs) on April 20, 2026.
Each RSU represents a contingent right to receive one Ordinary Share of the company upon vesting. According to the disclosure, these RSUs vest immediately and have no expiration date. Following this grant, the CFO directly holds 18,584 RSUs, reflecting a new equity-based incentive aligned with the company’s share performance.
ASCENTAGE PHARMA GROUP INTERNATIONAL filed an initial insider ownership report for Veet Misra, who serves as Chief Financial Officer. The available data lists Misra as the sole reporting person and shows no insider transactions or derivative positions in the excerpted information.
ASCENTAGE PHARMA GROUP INTERNATIONAL filed an amended insider ownership report for Chief Accounting Officer Jin Cao. The filing shows direct ownership of 5,400 Ordinary Shares, which had been inadvertently omitted previously, and 12,883 restricted stock units (RSUs).
Each RSU represents a contingent right to receive one Ordinary Share upon vesting. The RSUs vest in four equal installments on November 26 of 2026, 2027, 2028 and 2029, and do not have an expiration date.
Ascentage Pharma Group International filed a report describing its participation in the AACR 2026 Annual Meeting, where it is presenting four preclinical poster studies on combination cancer therapies. The work features three drug candidates: olverembatinib, APG-2449, and APG-5918 across hematologic malignancies and solid tumors.
The studies explore olverembatinib beyond its approved use in China for chronic myeloid leukemia, including endometrial carcinoma and mantle cell lymphoma, as well as APG-2449 in BRAF V600E-mutant tumors and APG-5918 in small-cell lung cancer. These preclinical data are intended to help guide ongoing and planned global registrational trials in multiple cancer indications.
Ascentage Pharma Group International reported the initial equity holdings of Chief Accounting Officer Jin Cao. The filing shows 12,883 restricted stock units (RSUs), each representing a contingent right to receive one Ordinary Share upon vesting.
The RSUs vest in four equal installments on November 26 of 2026, 2027, 2028 and 2029 and have no expiration date. The position is held directly and reflects equity-based compensation rather than an open-market share purchase or sale.